{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T14:52:46Z","timestamp":1783003966196,"version":"3.54.5"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,4,19]],"date-time":"2025-04-19T00:00:00Z","timestamp":1745020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,19]],"date-time":"2025-04-19T00:00:00Z","timestamp":1745020800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100006470","name":"Aristotle University of Thessaloniki","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006470","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Despite their increasing use and their proven efficacy in the treatment of rheumatoid arthritis (RA), Janus kinase (JAK) inhibitors have been questioned by credible cardiovascular safety concerns. To date, mechanistic links of cardiovascular complications to JAK inhibitors remain largely unexplored. We aimed to investigate the effect of JAK inhibition on coronary microvascular blood flow in a previously published cohort of treated patients with RA. We prospectively enrolled RA patients initiating treatment with JAK inhibitors. Study procedures were performed at baseline and repeated 3 months after treatment. Patients underwent applanation tonometry in the radial artery to assess subendocardial viability ratio (SEVR) otherwise known as Buckberg index, a noninvasive marker of myocardial perfusion. Thirteen patients with RA were enrolled, of whom 11 completed the study. All patients presented with at least one cardiovascular risk factor (e.g., age\u2009\u2265\u200965 years, history of current or past smoking, obesity, hypertension). No change in other than antirheumatic treatment was performed during the study, and no significant changes were observed in baseline characteristics other than triglyceride levels. Compared to baseline, three months treatment with JAK inhibitors did not significantly alter SEVR values [126 (102-144) % vs. 134 (106-251) %, <jats:italic>p<\/jats:italic>\u2009=\u20090.083]. Three months treatment with JAK inhibitors did not seem to significantly affect myocardial perfusion in a small RA cohort with cardiovascular risk factors, who would be presumably more vulnerable to adverse treatment-related cardiovascular effects. Larger studies with longer follow-up are needed to document the effects of JAK inhibitors on the myocardium.<\/jats:p>","DOI":"10.1007\/s00296-025-05862-y","type":"journal-article","created":{"date-parts":[[2025,4,19]],"date-time":"2025-04-19T05:17:10Z","timestamp":1745039830000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Effects of treatment with janus kinase inhibitors on coronary microvascular perfusion in patients with rheumatoid arthritis: an observational prospective cohort study"],"prefix":"10.1007","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5658-4629","authenticated-orcid":false,"given":"Panagiota","family":"Anyfanti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Angeloudi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleni","family":"Pagkopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Boutel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgia-Savina","family":"Moysidou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kleopatra","family":"Deuteraiou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleni","family":"Bekiari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Doumas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George D.","family":"Kitas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodoros","family":"Dimitroulas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,19]]},"reference":[{"key":"5862_CR1","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1056\/NEJMoa2109927","volume":"386","author":"SR Ytterberg","year":"2022","unstructured":"Ytterberg SR, Bhatt DL, Mikuls TR et al (2022) Cardiovascular and cancer risk with Tofacitinib in rheumatoid arthritis. N Engl J Med 386:316\u2013326. https:\/\/doi.org\/10.1056\/NEJMoa2109927","journal-title":"N Engl J Med"},{"key":"5862_CR2","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1136\/ard-2022-222259","volume":"82","author":"C Charles-Schoeman","year":"2023","unstructured":"Charles-Schoeman C, Buch MH, Dougados M et al (2023) Risk of major adverse cardiovascular events with Tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL surveillance. Ann Rheum Dis 82:119\u2013129. https:\/\/doi.org\/10.1136\/ard-2022-222259","journal-title":"Ann Rheum Dis"},{"key":"5862_CR3","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/ard-2022-223356","volume":"82","author":"JS Smolen","year":"2023","unstructured":"Smolen JS, Landew\u00e9 RBM, Bergstra SA et al (2023) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis 82:3\u201318. https:\/\/doi.org\/10.1136\/ard-2022-223356","journal-title":"Ann Rheum Dis"},{"key":"5862_CR4","unstructured":"European Medicines Agency (2022) EMA recommends measures to minimise risk of serious side effects with Janus kinase inhibitors for chronic inflammatory disorders. In: https:\/\/www.ema.europa.eu\/en\/news\/ema-recommends-measures-minimise-risk-serious-side-effects-janus-kinase-inhibitors-chronic-inflammatory-disorders"},{"key":"5862_CR5","unstructured":"F\u03bf\u03bfd and Drug Administration (2021) Janus Kinase (JAK) inhibitors: Drug Safety Communication - FDA Requires Warnings about Increased Risk of Serious Heart-related Events, Cancer, Blood Clots, and Death. In: https:\/\/www.fda.gov\/safety\/medical-product-safety-information\/janus-kinase-jak-inhibitors-drug-safety-communication-fda-requires-warnings-about-increased-risk"},{"key":"5862_CR6","doi-asserted-by":"publisher","first-page":"e138","DOI":"10.1016\/S2665-9913(24)00002-X","volume":"6","author":"MD Russell","year":"2024","unstructured":"Russell MD, Yang Z, Walter B et al (2024) The influence of safety warnings on the prescribing of JAK inhibitors. Lancet Rheumatol 6:e138\u2013e139. https:\/\/doi.org\/10.1016\/S2665-9913(24)00002-X","journal-title":"Lancet Rheumatol"},{"key":"5862_CR7","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1007\/s10067-017-3659-9","volume":"36","author":"P Anyfanti","year":"2017","unstructured":"Anyfanti P, Triantafyllou A, Gkaliagkousi E et al (2017) Subendocardial viability ratio in patients with rheumatoid arthritis: comparison with healthy controls and identification of prognostic factors. Clin Rheumatol 36:1229\u20131236. https:\/\/doi.org\/10.1007\/s10067-017-3659-9","journal-title":"Clin Rheumatol"},{"key":"5862_CR8","doi-asserted-by":"publisher","first-page":"2881","DOI":"10.1007\/s10067-023-06685-7","volume":"42","author":"P Anyfanti","year":"2023","unstructured":"Anyfanti P, Dimitriadou A, Dara A et al (2023) Circulating levels of galectin-3 and coronary microvascular perfusion in rheumatoid arthritis patients with suppressed inflammation. Clin Rheumatol 42:2881\u20132887. https:\/\/doi.org\/10.1007\/s10067-023-06685-7","journal-title":"Clin Rheumatol"},{"key":"5862_CR9","doi-asserted-by":"publisher","unstructured":"Xie H, Gao L, Fan F et al (2024) Research progress and clinical value of subendocardial viability ratio. J Am Heart Assoc 13. https:\/\/doi.org\/10.1161\/JAHA.123.032614","DOI":"10.1161\/JAHA.123.032614"},{"key":"5862_CR10","doi-asserted-by":"publisher","first-page":"R258","DOI":"10.1186\/ar4103","volume":"14","author":"A Sandoo","year":"2012","unstructured":"Sandoo A, Protogerou AD, Hodson J et al (2012) The role of inflammation, the autonomic nervous system and classical cardiovascular disease risk factors on subendocardial viability ratio in patients with RA: a cross-sectional and longitudinal study. Arthritis Res Ther 14:R258. https:\/\/doi.org\/10.1186\/ar4103","journal-title":"Arthritis Res Ther"},{"key":"5862_CR11","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1080\/00365513.2016.1177852","volume":"76","author":"T Dimitroulas","year":"2016","unstructured":"Dimitroulas T, Sandoo A, Hodson J et al (2016) In vivo microvascular and macrovascular endothelial function is not associated with Circulating dimethylarginines in patients with rheumatoid arthritis: a prospective analysis of the DRACCO cohort. Scand J Clin Lab Invest 76:331\u2013337. https:\/\/doi.org\/10.1080\/00365513.2016.1177852","journal-title":"Scand J Clin Lab Invest"},{"key":"5862_CR12","doi-asserted-by":"publisher","first-page":"834","DOI":"10.3390\/diagnostics14080834","volume":"14","author":"P Anyfanti","year":"2024","unstructured":"Anyfanti P, Angeloudi E, Dara A et al (2024) Non-Invasive assessment of Micro- and macrovascular function after initiation of JAK inhibitors in patients with rheumatoid arthritis. Diagnostics 14:834. https:\/\/doi.org\/10.3390\/diagnostics14080834","journal-title":"Diagnostics"},{"key":"5862_CR13","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1136\/annrheumdis-2019-216655","volume":"79","author":"JS Smolen","year":"2020","unstructured":"Smolen JS, Landew\u00e9 RBM, Bijlsma JWJ et al (2020) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis 79:685\u2013699. https:\/\/doi.org\/10.1136\/annrheumdis-2019-216655","journal-title":"Ann Rheum Dis"},{"key":"5862_CR14","doi-asserted-by":"publisher","first-page":"471","DOI":"10.31138\/mjr.33.4.471","volume":"33","author":"P Anyfanti","year":"2022","unstructured":"Anyfanti P, Angeloudi E, Pagkopoulou E, Bekiari E (2022) JAK Inhibition in patients with rheumatoid arthritis: haemodynamic effects and impact on Micro- and macrovascular function. Study design and rationale. Mediterr J Rheumatol 33:471. https:\/\/doi.org\/10.31138\/mjr.33.4.471","journal-title":"Mediterr J Rheumatol"},{"key":"5862_CR15","doi-asserted-by":"publisher","first-page":"10","DOI":"10.31138\/mjr.171023.rof","volume":"35","author":"S Partalidou","year":"2024","unstructured":"Partalidou S, Patoulias D, Deuteraiou K et al (2024) Risk of major adverse cardiovascular events and venous thromboembolism with JAK inhibitors versus TNF inhibitors in rheumatoid arthritis patients: A systematic review and Meta-Analysis. Mediterr J Rheumatol 35:10. https:\/\/doi.org\/10.31138\/mjr.171023.rof","journal-title":"Mediterr J Rheumatol"},{"key":"5862_CR16","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1136\/annrheumdis-2021-221915","volume":"81","author":"F Khosrow-Khavar","year":"2022","unstructured":"Khosrow-Khavar F, Kim SC, Lee H et al (2022) Tofacitinib and risk of cardiovascular outcomes: results from the safety of TofAcitinib in routine care patients with rheumatoid arthritis (STAR-RA) study. Ann Rheum Dis 81:798\u2013804. https:\/\/doi.org\/10.1136\/annrheumdis-2021-221915","journal-title":"Ann Rheum Dis"},{"key":"5862_CR17","doi-asserted-by":"publisher","first-page":"152572","DOI":"10.1016\/j.semarthrit.2024.152572","volume":"69","author":"O Al Tabaa","year":"2024","unstructured":"Al Tabaa O, Hecquet S, Thomas M et al (2024) Real-world assessment of the efficacy and tolerability profile of JAK inhibitors in difficult-to-treat rheumatoid arthritis. Semin Arthritis Rheum 69:152572. https:\/\/doi.org\/10.1016\/j.semarthrit.2024.152572","journal-title":"Semin Arthritis Rheum"},{"key":"5862_CR18","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1136\/ard-2023-224670","volume":"83","author":"R Aymon","year":"2024","unstructured":"Aymon R, Mongin D, Bergstra SA et al (2024) Evaluation of discontinuation for adverse events of JAK inhibitors and bDMARDs in an international collaboration of rheumatoid arthritis registers (the \u2018JAK-pot\u2019 study). Ann Rheum Dis 83:421\u2013428. https:\/\/doi.org\/10.1136\/ard-2023-224670","journal-title":"Ann Rheum Dis"},{"key":"5862_CR19","doi-asserted-by":"publisher","unstructured":"Song Y-K, Lee G, Hwang J et al (2023) Cardiovascular risk of Janus kinase inhibitors compared with biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis without underlying cardiovascular diseases: a nationwide cohort study. Front Pharmacol 14. https:\/\/doi.org\/10.3389\/fphar.2023.1165711","DOI":"10.3389\/fphar.2023.1165711"},{"key":"5862_CR20","doi-asserted-by":"publisher","first-page":"7390","DOI":"10.3390\/ijms21197390","volume":"21","author":"PJ Kotyla","year":"2020","unstructured":"Kotyla PJ, Islam MA, Engelmann M (2020) Clinical aspects of Janus kinase (JAK) inhibitors in the cardiovascular system in patients with rheumatoid arthritis. Int J Mol Sci 21:7390. https:\/\/doi.org\/10.3390\/ijms21197390","journal-title":"Int J Mol Sci"},{"key":"5862_CR21","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.3390\/biom12101483","volume":"12","author":"M Cz\u00f3kolyov\u00e1","year":"2022","unstructured":"Cz\u00f3kolyov\u00e1 M, Hamar A, Pusztai A et al (2022) Effects of One-Year Tofacitinib therapy on lipids and adipokines in association with vascular pathophysiology in rheumatoid arthritis. Biomolecules 12:1483. https:\/\/doi.org\/10.3390\/biom12101483","journal-title":"Biomolecules"},{"key":"5862_CR22","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1002\/acr.24108","volume":"73","author":"KP Liao","year":"2021","unstructured":"Liao KP, Huang J, He Z et al (2021) Coronary microvascular dysfunction in rheumatoid arthritis compared to diabetes mellitus and association with All-Cause mortality. Arthritis Care Res (Hoboken) 73:159\u2013165. https:\/\/doi.org\/10.1002\/acr.24108","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"5862_CR23","doi-asserted-by":"publisher","unstructured":"Amigues I, Russo C, Giles JT et al (2019) Myocardial microvascular dysfunction in rheumatoid arthritis. Circ Cardiovasc Imaging 12. https:\/\/doi.org\/10.1161\/CIRCIMAGING.117.007495","DOI":"10.1161\/CIRCIMAGING.117.007495"},{"key":"5862_CR24","doi-asserted-by":"publisher","unstructured":"Weber B, Weisenfeld D, Massarotti E et al (2024) Interplay between systemic inflammation, myocardial injury, and coronary microvascular dysfunction in rheumatoid arthritis: results from the LiiRA study. J Am Heart Assoc 13. https:\/\/doi.org\/10.1161\/JAHA.123.030387","DOI":"10.1161\/JAHA.123.030387"},{"key":"5862_CR25","doi-asserted-by":"publisher","unstructured":"Zavoriti A, Miossec P (2025) Understanding cardiovascular events with <\u2009scp\u2009>\u2009jak\u2009inhibitors: Tofacitinib reduces synovial and vascular inflammation but not the prothrombotic effects of inflammatory cytokines on endothelium. ACR Open Rheumatol 7. https:\/\/doi.org\/10.1002\/acr2.11790","DOI":"10.1002\/acr2.11790"},{"key":"5862_CR26","doi-asserted-by":"publisher","unstructured":"Zhang X, Chen S, Yin G et al (2024) The role of JAK\/STAT signaling pathway and its downstream influencing factors in the treatment of atherosclerosis. J Cardiovasc Pharmacol Ther 29. https:\/\/doi.org\/10.1177\/10742484241248046","DOI":"10.1177\/10742484241248046"},{"key":"5862_CR27","doi-asserted-by":"publisher","unstructured":"So\u00f3s B, Hamar A, Pusztai A et al (2022) Effects of Tofacitinib therapy on arginine and methionine metabolites in association with vascular pathophysiology in rheumatoid arthritis: A metabolomic approach. Front Med (Lausanne) 9. https:\/\/doi.org\/10.3389\/fmed.2022.1011734","DOI":"10.3389\/fmed.2022.1011734"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-025-05862-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00296-025-05862-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-025-05862-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T11:45:16Z","timestamp":1748000716000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00296-025-05862-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,19]]},"references-count":27,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,5]]}},"alternative-id":["5862"],"URL":"https:\/\/doi.org\/10.1007\/s00296-025-05862-y","relation":{},"ISSN":["1437-160X"],"issn-type":[{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,19]]},"assertion":[{"value":"13 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Institutional Review Board of Hippokration Hospital, Thessaloniki, Greece approved the study (protocol code 445\/29-12-21, date of approval 17 February 2022). Participants gave informed consent to participate in the study before inclusion. The study was conducted in accordance with the principles of the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and informed consent"}},{"value":"No part of this manuscript, including the text and graphics, are copied or published elsewhere in whole or in part.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}},{"value":"Panagiota Anyfanti, Elena Angeloudi, Eleni Pagkopoulou, Maria Boutel, Georgia-Savina Moysidou, Kleopatra Deuteraiou, Eleni Bekiari, Michael Doumas, and George D Kitas report no conflict of interest for this study. Theodoros Dimitroulas has received honoraria and advisory fees from Abbvie, Lilly, Pfizer and Sobi.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"111"}}